


Advanced Therapeutics within Everyone's Reach

CELLTRION IR Presentation

March & April 2025



Disclaimer

The financial information contained in this document is consolidated earnings results based on K-IFRS.

This document is provided for the convenience of investors only before the external audit is completed. The audit outcomes may cause some changes in this document.

This document contains 'forward-looking statements' related to the business performance, market condition, future events and plan. Therefore, the recipients of this document shall be aware that the forward-looking statements set forth herein may not correspond to the actual business performance of the company due to changes in the business/industry environment and the long-term business plan of the company.

The purpose of this document is not to recommend investment in the company. The company hereby expressly disclaims any and all liability resulting from investors' reliance on the information contained herein.



CONTENTS

- I. Business Overview
- II. Global Commercial Update
- III. Development and Production Strategy
- IV. Appendix





01


Business Overview

- 2024 at a Glance
- Biologics Global Market Sales
- Business Outlook
- Key Considerations

2024 at a Glance




* Young Portfolio includes Remsima SC, Yuflyma, Vegzelma, Zymfentra, Steqyema, etc.




1. Based on actual acquisition cost in 2024
2. Based on the closing price on the registration date of the cancellation in 2024



Biologics Global Market Sales




* Advanced: Remsima IV, Truxima, Herzuma / Young: Remsima SC, Yuflyma, Vegzelma, Zymfentra, Steqeyma, etc.
** 2022, 2023: Pre-merger Celltrion Healthcare's sales



Business Outlook


New portfolio launches + COGS improvement + Cost efficiency
= Quantitative & Qualitative Growth



Key Considerations

COGS Ratio

- '23.4Q 63% → '24.4Q 45%* → '25.4Q(E) 20% range
- ① High-cost inventory depletion, ② Expansion of TI products and Plant 3 production, ③ Completion of amortization for advanced product development costs is expected to accelerate cost ratio improvement



Operating Profit

- 2025(E) operating profit is projected to increase 2-3 times or more, driven by cost improvements, completion of merger-related sales rights amortization and top-line growth



* COGS ratio excluding one-time factors, such as initial operating costs for the launch of the plant 3




02

Global Commercial Update


- Biosimilar Portfolio & Pipeline
- Global Commercial Update

Biosimilar Portfolio & Pipeline


Increasing Market Presence via Biosimilar Expansion & Product Differentiation



Biosimilar Timeline



Target Pipeline Market Size





1. Intravenous injection
2. Subcutaneous injection
3. Intravitreal injection

* Combined sales of 22 original products in the pipelines
** Source: IQVIA

Remsima / Inflectra (Infliximab IV)


Maintaining a strong and stable presence in the global market




*Based on Infliximab IV Market (Excluding SC) *Market shares are based on prescription volume *Source: IQVIA

Remsima SC (Infliximab SC)

Remsima SC captures a 25% M/S in EU5, while combined IV and SC M/S nears 80%
Prescription expansion accelerates across Europe beyond EU5



* Data based on prescription volume * Source: IQVIA * EU5: UK, Spain, France, Germany, Italy



* Data based on SC dose-adjusted prescription volume * Source: IQVIA


Remsima M/S in EU5*

*Total M/S of Remsima IV & SC


	UK		France		Spain		Germany		Italy
	88.8%		80.0%		75.8%		73.8%		56.2%

Truxima (Rituximab) & Herzuma (Trastuzumab)

Truxima secures a 30% M/S in Europe and the US
Herzuma maintains its No. 1 position with a continued rise in M/S across Europe and Japan




1. The U.S. market share data is based on IQVIA from 4Q23 onwards due to the discontinuation of data provision by Symphony Health
* Market Share based on prescription volume * Source: IQVIA, Symphony Health




* Market Share based on prescription volume * Source: IQVIA, Market DATA

Yuflyma (Adalimumab)

Europe drives growth with country-specific bidding strategies
US expands sales via Dual WAC and diversified distribution channel




* Market Share based on prescription volume * Source: IQVIA




* ~ 4Q23: pre-merger Celltrion Healthcare's sales
1Q24~ : Post-merger Celltrion's sales

Vegzelma (Bevacizumab)

Leading Europe with No. 1 M/S through direct sales and cost efficiency,
with balanced sales growth across North America and Asia





* Market Share based on prescription volume * Source: IQVIA



* ~ 4Q23: pre-merger Celltrion Healthcare's sales
1Q24~: post-merger Celltrion's sales

Zymfentra (Infliximab SC)

As Zymfentra's formulary listing with PBM-affiliated insurers expands, the prescription volume continues to rise, shipment volume also grows significantly



* The standard unit of IQVIA(Pack Unit) is converted to the number of syringe
* Source: IQVIA SMART NSP(National Sales Perspectives), Celltrion

03

Development and Production Strategy

- Biosimilar R&D Update
- Novel Drug Pipeline
- IND Submission Timelines for Novel Drug Pipeline
- Celltrion BioSolutions

Biosimilar R&D Update

R&D Progress

Indication	Pipeline	Global Market size (2023)	R&D Status	
			US	EU
Autoimmune Diseases	 SteQeyma ustekinumab	\$20.2bn	Approved (Dec. 2024)	Approved (Aug. 2024)
	 Avtozma tocilizumab	\$3.2bn	Approved (Jan. 2025)	Approved (Feb. 2025)
	CT-P53 (biosimilar of OCREVUS®)	\$7.5bn	In Phase 3 Clinical Trial	
	CT-P55 (biosimilar of COSENTYX®)	\$7.7bn	IND for Phase 3 Approved (Aug. 2024)	IND for Phase 3 Approved (Feb. 2025)
AMD ¹	 Eydenzelt aflibercept	\$9.4bn	BLA under review (Jun. 2023)	Approved (Feb. 2025)
Asthma, CIU ²	 Omlyclo omalizumab	\$4.4bn	BLA under review (Apr. 2024)	Approved (May. 2024)
Osteoporosis	 Stoboclo denosumab  Osenvelt denosumab	\$6.8bn	Approved (Feb. 2025)	Approved (Feb. 2025)
NSCLC ³	CT-P51 (biosimilar of KEYTRUDA®)	\$28.2bn	IND for Phase 3 Approved (Aug. 2024)	IND for Phase 3 Approved (Dec. 2024)
Multiple Myeloma	CT-P44 (biosimilar of DARZALEX®)	\$9.7bn	IND for Phase 3 Approved (Dec. 2024)	IND for Phase 3 under review (Nov. 2024)

Portfolio Status



Immunology

TNF-α
REMSIMA IV

TNF-α
REMSIMA SC

TNF-α
YUFLYMA

IL-12/23
STEQEYMA

IL-6
AVTOZMA

CD20
OCREVUS® biosimilar

IL-17A
COSENTYX® biosimilar

7



Oncology

CD20
TRUXIMA

HER2
HERZUMA

VEGF
VEGZELMA

PD-1
KEYTRUDA® biosimilar

CD-38
DARZALEX® biosimilar

5



Other Therapeutic Areas

IgE
OMLYCLO

VEGF
EYDENZELT

RANKL
STOBOCLO & OSENVELT

3



Undisclosed Pipelines

UNDISCLOSED

UNDISCLOSED

UNDISCLOSED

UNDISCLOSED


UNDISCLOSED

UNDISCLOSED

7


1. AMD: Age-related Macular Degeneration 2. CIU: Chronic Idiopathic Urticaria 3. NSCLC: Non-Small Cell Lung Cancer
*Source: IQVIA, J&J(DARZALEX), Regeneron(EYLEA)

Novel Drug Pipeline : ADC & Multi-specific Antibodies




IND Submission Timelines for Novel Drug Pipeline

● ADC ● Multispecific Antibody --- IND Submission



1. NSCLC: Non-Small Cell Lung Cancer

Establishment of CDMO Subsidiary “Celltrion BioSolutions”



04

Appendix

- Biologics Portfolio & Pipeline List
- Production Facility & Capacity
- Global Presence
- Shareholder Return Policy
- Earnings Summary
- Quarterly Sales Mix

Biotherapeutics Portfolio & Pipeline List

Category	Product	Molecule / Modality	Original	Indications	US Status	EU Status
Biosimilar	Remsima/ Inflectra	Infliximab	Remicade®	Rheumatoid Arthritis(RA), Ulcerative Colitis(UC), Crohn's Disease(CD), etc.	2H16 Launched	1H13 Launched
	Remsima SC	Infliximab	Remicade®	Rheumatoid Arthritis(RA), Ulcerative Colitis(UC), Crohn's Disease(CD), etc.	-	1H20 Launched
	Yuflyma	Adalimumab	Humira®	Rheumatoid Arthritis(RA), Ulcerative Colitis(UC), Crohn's Disease(CD), etc.	1H23 Launched	1H21 Launched
	Truxima	Rituximab	Rituxan®/ MabThera®	Non-Hodgkin's Lymphoma(NHL), Chronic Lymphocytic Leukemia(CLL), etc.	2H19 Launched	1H17 Launched
	Herzuma	Trastuzumab	Herceptin®	HER2-Positive Metastatic Breast Cancer(MBC), Early Breast Cancer(EBC), etc.	1H20 Launched	1H18 Launched
	Vegzelma	Bevacizumab	Avastin®	Metastatic Colorectal Cancer(MCC), Non-Small Cell Lung Cancer(NSNLC), etc.	1H23 Launched	2H22 Launched
	SteQeyma	Ustekinumab	Stelara®	Psoriasis(Ps), Psoriatic Arthritis(PsA), Ulcerative Colitis(UC), Crohn's Disease(CD), etc.	2H24 Approved	2H24 Launched
	Omlyclo	Omalizumab	Xolair®	Allergic Asthma, Chronic Spontaneous Urticaria(CSU), etc.	Under Review	1H24 Approved
	Eydenzelt	Aflibercept	Eylea®	Wet age-related Macular Degeneration(AMD), Diabetic Macular Edema(DME), etc.	Under Review	1H25 Approved
	Stoboclo & Osenvelt	Denosumab	Prolia® & Xgeva®	Osteoporosis, Multiple Myeloma(MM), Giant Cell Tumor(GCT), etc.	1H25 Approved	1H25 Approved
	Avtozma	Tocilizumab	Actemra®	Rheumatoid Arthritis(RA), Giant Cell Arteritis(GCA), Systemic Juvenile Idiopathic Arthritis(SJIA), etc.	1H25 Approved	1H25 Approved
	CT-P53	Ocrelizumab	Ocrevus®	Multiple Sclerosis(MS)	In Clinical Phase 3	
	CT-P55	Secukinumab	Cosentyx®	Plaque Psoriasis(PsO), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis, (nr-axSpA), Entesitis-Related Arthritis (ERA), Hidradenitis Suppurative (HS) etc.	In Clinical Phase 3	
	CT-P51	Pembrolizumab	Keytruda®	Non-Small Cell Lung Cancer(NSNLC), Melanoma, Urothelial Carcinoma etc.	In Clinical Phase 3	
Novel Drug	Zymfentra	Infliximab	-	Ulcerative Colitis(UC), Crohn's Disease(CD)	1H24 Launched	-
	CT-P70	anti-cMET Topo1i-based ADC	-	Solid Tumors(Non-small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, etc.)	FDA IND application for Global Clinical Phase 1 Approved	

Production Facility & Capacity

250,000L of Own Drug Substance Capacity
Sufficient to Meet Demand for Successor Pipelines



100,000L

12,500L X 8 lines

- First to be approved by US FDA as animal cell culture facility in Asia



90,000L

15,000L X 6 lines

- Capable of manufacturing drug substance and fill and finish of drug product



60,000L

7,500L X 8 lines


- Small-scale production for multiple products along with diversification of product portfolio
- Commercial operation to begin in 4Q24

Global Presence




Shareholder Return Policy

Increase in Shareholder Return



Increase in Cash Dividend Target

● EBITDA – CAPEX ○ Cash Dividend (% of EBITDA – CAPEX) [Unit : KRW Billion]



* In FY21 and FY22, stock dividends of approx. 520B KRW and 884.6B KRW were issued along with cash dividends
 * Target cash dividend set based on (EBITDA – CAPEX) given large R&D and CAPEX needs of the business

Earnings Summary: Consolidated

[Unit: KRW billion]

	Quarterly								Yearly		
	1Q23	2Q23	3Q23	4Q23	1Q24	2Q24	3Q24	4Q24	FY2022	FY2023	FY2024
Sales	598	524	672	383	737	875	882	1,064	2,284	2,176	3,557
Cost of Sales	333	248	302	241	430	507	419	520	1,251	1,125	1,876
Gross Profit	264	276	370	141	307	368	463	544	1,033	1,052	1,682
GP Margin	44.2%	52.7%	55.1%	36.9%	41.6%	42.1%	52.5%	51.1%	45.2%	48.3%	47.3%
SG&A	82	93	103	123	291	295	256	347	385	400	1,190
- R&D Expenses	30	39	42	50	49	36	53	61	140	161	200
Operating Profit	182	183	268	18	15	72	208	196	647	651	492
OP Margin	30.5%	34.9%	39.8%	4.8%	2.1%	8.3%	23.5%	18.5%	28.3%	29.9%	13.8%
Other Non-operating Profit/Loss*	21	3	6	(22)	6	41	(19)	80	(32)	8	105
Financial Income/Loss	5	4	9	(6)	(1)	(7)	(11)	(4)	11	11	(24)
Profit before Income Tax	208	190	283	(10)	20	104	178	274	626	671	576
Net Profit	167	150	221	0.4	21	78	84	236	543	540	419
NP Margin	28.0%	28.8%	32.9%	0.1%	2.8%	9.0%	9.5%	22.1%	23.8%	24.8%	11.8%

* Other non-operation profit/loss includes the net gain/loss on equity method valuation

Earnings Summary: Non-Consolidated

[Unit: KRW billion]

	Quarterly								Yearly		
	1Q23	2Q23	3Q23	4Q23	1Q24	2Q24	3Q24	4Q24	FY2022	FY2023	FY2024
Sales	536	423	600	315	638	973	1,040	1,058	1,937	1,873	3,709
Cost of Sales	296	197	266	197	457	493	458	493	1,052	955	1,901
Gross Profit	239	226	334	118	181	480	582	565	885	918	1,808
GP Margin	44.7%	53.5%	55.7%	37.5%	28.3%	49.3%	56.0%	53.4%	45.7%	49.0%	48.7%
SG&A	54	63	70	92	152	167	120	157	267	280	597
- R&D Expenses	28	38	38	47	39	39	47	60	131	151	186
Operating Profit	186	163	264	26	29	313	462	408	619	638	1,211
OP Margin	34.6%	38.5%	44.0%	8.2%	4.5%	32.2%	44.4%	38.5%	31.9%	34.1%	32.6%
Other Non-operating Profit/Loss	23	8	10	(14)	12	(5)	(27)	77	(30)	27	58
Financial Income/Loss	6	5	10	(5)	9	(2)	(4)	1	17	17	3
Profit before Income Tax	214	176	285	7	49	306	431	486	606	682	1,272
Net Profit	172	140	223	29	61	245	321	379	511	563	1,005
NP Margin	32.1%	33.1%	37.1%	9.1%	9.5%	25.1%	30.8%	35.8%	26.4%	30.1%	27.1%

Quarterly Sales Mix

[Unit: KRW billion]

	Adjusted*				Publicly Disclosed							
	1Q23	2Q23	3Q23	4Q23	1Q23	2Q23	3Q23	4Q23	1Q24	2Q24	3Q24	4Q24
Sales	635	620	833	585	598	524	672	383	737	875	882	1,064
Biologics	450	497	623	400	413	380	462	198	651	774	810	873
Advanced Products	359	366	462	269	246	200	206	146	437	541	468	470
Remsima IV	239	239	295	220	114	90	171	145	299	363	317	289
Truxima	74	82	108	5	113	64	16	0	101	115	102	132
Herzuma	46	45	59	44	19	46	20	1	37	62	49	49
Young Products	91	131	161	132	167	180	256	52	214	233	342	403
Remsima SC	66	81	101	74	165	30	86	9	112	111	171	170
Yuflyma	21	32	47	42	2	-	129	4	67	80	94	108
Vegzelma	4	18	13	15	-	-	41	40	35	40	69	77
Zymfentra	-	-	-	-	-	-	-	-	-	2	6	28
Steqeyma	-	-	-	-	-	36	-	-	-	-	2	18
Others	-	-	-	-	-	114	-	-	-	-	-	2
Non-Biologics	185	123	210	185	185	144	210	185	86	101	72	190
CT Pharm/Chemical	96	95	93	88	96	116	93	88	81	95	65	79
CMO	-	-	60	45	-	-	60	45	-	-	-	106
Others	89	28	57	52	89	28	57	52	5	6	7	5

* For comparability, 2023 Biopharmaceutical sales are the pre-merger Celltrion Healthcare's sales, while non-biopharmaceutical sales are Celltrion's sales

Advanced Therapeutics within Everyone's Reach

Thank you

